{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:54:35Z","timestamp":1759366475825,"version":"build-2065373602"},"reference-count":22,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Revue de M\u00e9decine Interne"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.revmed.2022.08.009","type":"journal-article","created":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T03:54:48Z","timestamp":1662436488000},"page":"739-742","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Life-threatening chlorpromazine-induced acquired haemophilia A in a patient with a cavernous malformation involving the medulla oblongata"],"prefix":"10.1016","volume":"43","author":[{"given":"R.","family":"Stammler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Ackermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Vasse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Verrat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"David","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Horodyckid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Gratieux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Marroun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Groh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Roumier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Paule","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.revmed.2022.08.009_bib0115","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/ajh.24777","article-title":"Acquired hemophilia A: updated review of evidence and treatment guidance","volume":"92","author":"Kruse-Jarres","year":"2017","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.revmed.2022.08.009_bib0120","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/ajh.20390","article-title":"Acquired hemophilia A: a concise review","volume":"80","author":"Franchini","year":"2005","journal-title":"Am J Hematol"},{"issue":"4","key":"10.1016\/j.revmed.2022.08.009_bib0125","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1111\/hae.12138","article-title":"Outcome of acquired haemophilia in France: the prospective SACHA (Surveillance des Auto antiCorps au cours de l\u2019H\u00e9mophilie Acquise) registry","volume":"19","author":"Borg","year":"2013","journal-title":"Haemophilia"},{"issue":"1","key":"10.1016\/j.revmed.2022.08.009_bib0130","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1182\/blood-2012-02-409185","article-title":"Immunosuppression for acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2)","volume":"120","author":"Collins","year":"2012","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.revmed.2022.08.009_bib0135","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1182\/blood-2014-07-587089","article-title":"Prognostic factors for remission of and survival in acquired hemophilia A (AHA): results from the GTH-AH 01\/2010 study","volume":"125","author":"Tiede","year":"2015","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.revmed.2022.08.009_bib0140","first-page":"RA55","article-title":"Drug-induced anti-factor VIII antibodies: a systematic","volume":"13","author":"Franchini","year":"2007","journal-title":"Med Sci Monit"},{"key":"10.1016\/j.revmed.2022.08.009_bib0145","doi-asserted-by":"crossref","first-page":"365","DOI":"10.3389\/fonc.2019.00365","article-title":"Editorial: management of immune-related adverse events for patients undergoing treatment with checkpoint inhibitors","volume":"9","author":"Rapoport","year":"2019","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.revmed.2022.08.009_bib0150","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.annder.2020.09.577","article-title":"Onset of acquired haemophilia A after omalizumab treatment in severe bullous pemphigoid\u00a0\u2013\u00a0a report on two cases successfully treated with mycophenolate mofetil","volume":"148","author":"Mangin","year":"2021","journal-title":"Ann Dermatol Venereol"},{"issue":"2","key":"10.1016\/j.revmed.2022.08.009_bib0155","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1080\/09273948.2020.1808227","article-title":"Adalimumab-associated acquired hemophilia in a patient with scleritis","volume":"30","author":"Liberman","year":"2022","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.revmed.2022.08.009_bib0160","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2017-223016","article-title":"Acquired haemophilia A complicating alemtuzumab therapy for multiple sclerosis","author":"McCaughan","year":"2017","journal-title":"BMJ Case Rep"},{"issue":"351","key":"10.1016\/j.revmed.2022.08.009_bib0165","first-page":"16","article-title":"Chlorpromazine jaundice: analysis of twenty-two cases","volume":"22","author":"Werther","year":"1957","journal-title":"Am J Med"},{"issue":"6","key":"10.1016\/j.revmed.2022.08.009_bib0170","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1002\/hep.1840200610","article-title":"Chlorpromazine-induced vanishing bile duct syndrome leading to biliary cirrhosis","volume":"20","author":"Moradpour","year":"1994","journal-title":"Hepatology"},{"key":"10.1016\/j.revmed.2022.08.009_bib0175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2009\/495863","article-title":"Drug-induced hematologic syndromes","volume":"2009","author":"Mintzer","year":"2009","journal-title":"Adv Hematol"},{"issue":"6","key":"10.1016\/j.revmed.2022.08.009_bib0180","doi-asserted-by":"crossref","first-page":"e586","DOI":"10.1097\/HS9.0000000000000586","article-title":"New developments in diagnosis and management of acquired hemophilia and acquired Von Willebrand syndrome","volume":"5","author":"Leebeek","year":"2021","journal-title":"HemaSphere"},{"issue":"6","key":"10.1016\/j.revmed.2022.08.009_bib0185","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1001\/jama.1972.03200190039010","article-title":"Chlorpromazine-induced systemic lupus erythematosus: case report and review of the literature","volume":"221","author":"Dubois","year":"1972","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.revmed.2022.08.009_bib0190","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/ajh.2830130204","article-title":"Chlorpromazine-induced lupus anticoagulant and associated immunologic abnormalities","volume":"13","author":"Canoso","year":"1982","journal-title":"Am J Hematol"},{"issue":"6","key":"10.1016\/j.revmed.2022.08.009_bib0195","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1006\/jaut.1997.0165","article-title":"HLA-DR7 in association with chlorpromazine-induced lupus anticoagulant (LA)","volume":"10","author":"Vargas-Alarc\u00f3n","year":"1997","journal-title":"J Autoimmun"},{"issue":"6","key":"10.1016\/j.revmed.2022.08.009_bib0200","first-page":"ED21","article-title":"Acquired inhibitor of factor VIII presenting as delayed wound healing","volume":"11","author":"Nayar","year":"2017","journal-title":"J Clin Diagn Res"},{"issue":"3","key":"10.1016\/j.revmed.2022.08.009_bib0205","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/j.1365-2141.1978.tb05816.x","article-title":"IgM inhibitors of the contact activation phase of coagulation in chlorpromazine-treated patients","volume":"40","author":"Zucker","year":"1978","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.revmed.2022.08.009_bib0210","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1182\/blood-2006-06-029850","article-title":"Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors\u2019 Organisation","volume":"109","author":"Collins","year":"2007","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.revmed.2022.08.009_bib0215","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.3324\/haematol.2019.230771","article-title":"International recommendations on the diagnosis and treatment of acquired hemophilia A","volume":"105","author":"Tiede","year":"2020","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.revmed.2022.08.009_bib0220","first-page":"CD011907","article-title":"Rituximab for eradicating inhibitors in people with acquired haemophilia A. Cochrane Cystic Fibrosis and Genetic Disorders Group, editor","volume":"23","author":"Remmington","year":"2021","journal-title":"Cochrane Database Syst Rev"}],"container-title":["La Revue de M\u00e9decine Interne"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866322006312?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866322006312?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:45:24Z","timestamp":1759337124000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0248866322006312"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":22,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S0248866322006312"],"URL":"https:\/\/doi.org\/10.1016\/j.revmed.2022.08.009","relation":{},"ISSN":["0248-8663"],"issn-type":[{"type":"print","value":"0248-8663"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Life-threatening chlorpromazine-induced acquired haemophilia A in a patient with a cavernous malformation involving the medulla oblongata","name":"articletitle","label":"Article Title"},{"value":"La Revue de M\u00e9decine Interne","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.revmed.2022.08.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Soci\u00e9t\u00e9 Nationale Fran\u00e7aise de M\u00e9decine Interne (SNFMI). Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}